{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:46:22Z","timestamp":1791233182944,"version":"4.1.0"},"reference-count":53,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["ACS 134386-RSG-20-038-01-DDC"],"award-info":[{"award-number":["ACS 134386-RSG-20-038-01-DDC"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA075115"],"award-info":[{"award-number":["R01CA075115"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21877060"],"award-info":[{"award-number":["21877060"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,3,15]]},"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Bladder cancer is a common disease worldwide with most patients presenting with the non-muscle-invasive form (NMIBC) at initial diagnosis. Postoperational intravesical instillation of BCG is carried out for patients with high-risk disease to reduce tumor recurrence and progression to muscle invasive disease. However, BCG can also have side effects or be ineffective in some patients because it cannot enter the cancer cells. Thus, to improve the efficacy of BCG immunotherapy is the long-term pursuit of the bladder cancer field.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>To increase the adhesion of BCG to the urothelium we overexpressed FimH, a mannose binding protein naturally used by uropathogenic <jats:italic>Escherichia coli<\/jats:italic> to adhere to human urothelium, onto the surface of BCG. The adhesion\/internalization ability of rBCG-S.FimH was examined in mouse bladder by fluorescence microscopy. Preclinical evaluation of antitumor efficacy was carried out in orthotopic mouse models of bladder cancer and in human peripheral blood mononuclear cells. Mechanistic studies were carried out using toll-like receptor 4 (TLR4) knockout mice. Immune cells and cytokines in the serum, tumor and lymph nodes were analyzed by flow cytometry, PCR, ELISA and ELISPOT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>rBCG-S.FimH exhibited markedly improved adhesion and more rapid internalization into urothelial cells than wild-type BCG, resulting in more potent antitumor activity in orthotopic murine models of bladder cancer. To our surprise, rBCG-S.FimH elicited a much more prominent Th1-biased immune response known to be positively correlated with BCG efficacy. Mechanistic studies using TLR4 knockout mouse showed that rBCG-S.FimH could induce enhanced dendritic cell activation and tumor antigen-specific immune response in a TLR4-dependent manner. Furthermore, human peripheral blood mononuclear cells stimulated by rBCG-S.FimH also showed better tumoricidal effects than those using wild-type BCG.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>rBCG-S.FimH is a novel BCG strain with significantly improved efficacy against bladder cancer. Since intravesical BCG immunotherapy is the first-line treatment for NMIBC, which accounts for more than 70% of all bladder cancer cases, our results provide a compelling rationale for clinical development.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-003939","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T12:21:27Z","timestamp":1648729287000},"page":"e003939","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":28,"title":["FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer"],"prefix":"10.1136","volume":"10","author":[{"given":"Yang","family":"Zhang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Huo","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Urology, the First Affiliated Hospital with Nanjing Medical University (Jiangsu Province Hospital), Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Jia","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiju","family":"Huang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu A","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell and Developmental Biology, University of California Santa Cruz, Santa Cruz, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Theodorescu","sequence":"additional","affiliation":[{"name":"Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA"},{"name":"Department of Surgery (Urology), Cedars-Sinai Medical Center, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Urology, the First Affiliated Hospital with Nanjing Medical University (Jiangsu Province Hospital), Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengchao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, the First Affiliated Hospital with Nanjing Medical University (Jiangsu Province Hospital), Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6029-224X","authenticated-orcid":false,"given":"Chao","family":"Yan","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, China"},{"name":"Engineering Research Center of Protein and Peptide Medicine, Ministry of Education, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"2025100309163309000_10.3.e003939.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.05.041"},{"key":"2025100309163309000_10.3.e003939.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.07.033"},{"key":"2025100309163309000_10.3.e003939.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-009-0383-3"},{"key":"2025100309163309000_10.3.e003939.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2008.10.024"},{"key":"2025100309163309000_10.3.e003939.5","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000062605.92268.c6"},{"key":"2025100309163309000_10.3.e003939.6","doi-asserted-by":"publisher","DOI":"10.1586\/era.09.35"},{"key":"2025100309163309000_10.3.e003939.7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00345-011-0681-4","article-title":"Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy","volume":"29","author":"Yates","year":"2011","journal-title":"World J Urol"},{"key":"2025100309163309000_10.3.e003939.8","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/530121"},{"key":"2025100309163309000_10.3.e003939.9","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.56.12.3046-3051.1988"},{"key":"2025100309163309000_10.3.e003939.10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00716","article-title":"Exploring the Potential Role of Moonlighting Function of the Surface-Associated Proteins From Mycobacterium bovis BCG Moreau and Pasteur by Comparative Proteomic","volume":"10","author":"Pagani","year":"2019","journal-title":"Front Immunol"},{"key":"2025100309163309000_10.3.e003939.11","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0022-5347(17)42445-1","article-title":"Role of fibronectin in intravesical BCG therapy for superficial bladder cancer","volume":"139","author":"Ratliff","year":"1988","journal-title":"J Urol"},{"key":"2025100309163309000_10.3.e003939.12","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0022-5347(17)38621-4","article-title":"Characterization of fibronectin attachment by a human transitional cell carcinoma line, T24","volume":"145","author":"Coplen","year":"1991","journal-title":"J Urol"},{"key":"2025100309163309000_10.3.e003939.13","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.15"},{"key":"2025100309163309000_10.3.e003939.14","doi-asserted-by":"publisher","DOI":"10.1159\/000355628"},{"key":"2025100309163309000_10.3.e003939.15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02350","article-title":"IL-2 Restores T-Cell Dysfunction Induced by Persistent Mycobacterium tuberculosis Antigen Stimulation","volume":"10","author":"Liu","year":"2019","journal-title":"Front Immunol"},{"key":"2025100309163309000_10.3.e003939.16","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00243-08"},{"key":"2025100309163309000_10.3.e003939.17","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/j.1398-9995.2005.00826.x","article-title":"Recombinant Mycobacterium bovis BCG producing IL-18 reduces IL-5 production and bronchoalveolar eosinophilia induced by an allergic reaction","volume":"60","author":"Biet","year":"2005","journal-title":"Allergy"},{"key":"2025100309163309000_10.3.e003939.18","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-006-9395-0"},{"key":"2025100309163309000_10.3.e003939.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02522.x"},{"key":"2025100309163309000_10.3.e003939.20","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.3892\/etm.2017.4273","article-title":"Recombinant Bacille Calmette-Gu\u00e9rin coexpressing Ag85B-IFN-\u03b3 enhances the cell-mediated immunity in C57BL\/6 mice","volume":"13","author":"Liu","year":"2017","journal-title":"Exp Ther Med"},{"key":"2025100309163309000_10.3.e003939.21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.intimp.2016.03.007","article-title":"Antitumor activity of recombinant Bacille Calmette-Gu\u00e9rin secreting interleukin-15-Ag85B fusion protein against bladder cancer","volume":"35","author":"Takeuchi","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"2025100309163309000_10.3.e003939.22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/9630793","article-title":"A Bivalent Recombinant Mycobacterium bovis BCG Expressing the S1 Subunit of the Pertussis Toxin Induces a Polyfunctional CD4+ T Cell Immune Response","volume":"2019","author":"Kanno","year":"2019","journal-title":"Biomed Res Int"},{"key":"2025100309163309000_10.3.e003939.23","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S202006"},{"key":"2025100309163309000_10.3.e003939.24","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.juro.2015.11.073","article-title":"The dose-response relationship of Bacillus Calmette-Gu\u00e9rin and urothelial carcinoma cell biology","volume":"195","author":"Shah","year":"2016","journal-title":"J Urol"},{"key":"2025100309163309000_10.3.e003939.25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602026"},{"key":"2025100309163309000_10.3.e003939.26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0022-5347(17)36052-4","article-title":"Fibronectin expression on surgical specimens correlated with the response to intravesical Bacillus Calmette-Guerin therapy","volume":"149","author":"Fleischmann","year":"1993","journal-title":"J Urol"},{"key":"2025100309163309000_10.3.e003939.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65154-1"},{"key":"2025100309163309000_10.3.e003939.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052835","article-title":"Chaperone-Usher fimbriae of Escherichia coli","volume":"8","author":"Wurpel","year":"2013","journal-title":"PLoS One"},{"key":"2025100309163309000_10.3.e003939.29","doi-asserted-by":"publisher","DOI":"10.1038\/nature22972"},{"key":"2025100309163309000_10.3.e003939.30","doi-asserted-by":"publisher","DOI":"10.1038\/351456a0"},{"key":"2025100309163309000_10.3.e003939.31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1128\/cdli.3.6.761-768.1996","article-title":"A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein","volume":"3","author":"Luo","year":"1996","journal-title":"Clin Diagn Lab Immunol"},{"key":"2025100309163309000_10.3.e003939.32","article-title":"An orthotopic bladder cancer model for gene delivery studies","author":"Kasman","year":"2013","journal-title":"J Vis Exp"},{"key":"2025100309163309000_10.3.e003939.33","doi-asserted-by":"crossref","first-page":"F1422","DOI":"10.1152\/ajprenal.00350.2018","article-title":"Void spot assay: recommendations on the use of a simple micturition assay for mice","volume":"315","author":"Hill","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025100309163309000_10.3.e003939.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2015.03.007"},{"key":"2025100309163309000_10.3.e003939.35","doi-asserted-by":"crossref","DOI":"10.1002\/phy2.260","article-title":"The mouse cyclophosphamide model of bladder pain syndrome: tissue characterization, immune profiling, and relationship to metabotropic glutamate receptors","volume":"2","author":"Golubeva","year":"2014","journal-title":"Physiol Rep"},{"key":"2025100309163309000_10.3.e003939.36","doi-asserted-by":"publisher","DOI":"10.1084\/jem.178.1.197"},{"key":"2025100309163309000_10.3.e003939.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.08.039"},{"key":"2025100309163309000_10.3.e003939.38","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12274"},{"key":"2025100309163309000_10.3.e003939.39","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.4049\/jimmunol.163.8.4246","article-title":"Role of IL-12 in the induction and potentiation of IFN-gamma in response to Bacillus Calmette-Gu\u00e9rin","volume":"163","author":"O'Donnell","year":"1999","journal-title":"J Immunol"},{"key":"2025100309163309000_10.3.e003939.40","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2002.01734.x"},{"key":"2025100309163309000_10.3.e003939.41","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-4666(02)00490-8"},{"key":"2025100309163309000_10.3.e003939.42","doi-asserted-by":"publisher","DOI":"10.1186\/s13567-016-0367-4"},{"key":"2025100309163309000_10.3.e003939.43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4081\/aiua.2013.4.157","article-title":"Dendritic cells in blood and urine samples from bladder cancer patients undergoing BCG immunotherapy","volume":"85","author":"Rossi","year":"2013","journal-title":"Arch Ital Urol Androl"},{"key":"2025100309163309000_10.3.e003939.44","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15030-4","article-title":"Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat Commun"},{"key":"2025100309163309000_10.3.e003939.45","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0022-5347(05)68351-6","article-title":"Mutated ras p21 as a target for cancer therapy in mouse transitional cell carcinoma","volume":"162","author":"Luo","year":"1999","journal-title":"J Urol"},{"key":"2025100309163309000_10.3.e003939.46","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00002371-200409000-00001","article-title":"Escape from immune surveillance does not result in tolerance to tumor-associated antigens","volume":"27","author":"Melchionda","year":"2004","journal-title":"J Immunother"},{"key":"2025100309163309000_10.3.e003939.47","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.archoralbio.2019.02.009","article-title":"Fimh as a mucosal adjuvant enhances persistent antibody response and protective efficacy of the anti-caries vaccine","volume":"101","author":"Liu","year":"2019","journal-title":"Arch Oral Biol"},{"key":"2025100309163309000_10.3.e003939.48","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1021\/acs.molpharmaceut.8b00691","article-title":"TLR4-Based immunotherapeutics in cancer: a review of the achievements and shortcomings","volume":"15","author":"Shetab Boushehri","year":"2018","journal-title":"Mol Pharm"},{"key":"2025100309163309000_10.3.e003939.49","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201344300"},{"key":"2025100309163309000_10.3.e003939.50","doi-asserted-by":"publisher","DOI":"10.4161\/onci.20931"},{"key":"2025100309163309000_10.3.e003939.51","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0103026"},{"key":"2025100309163309000_10.3.e003939.52","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M105927200"},{"key":"2025100309163309000_10.3.e003939.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2013.11.007"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003939","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:16:41Z","timestamp":1759508201000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":53,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,31]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/jitc-2021-003939"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003939","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}